TrialPath
Inflammatory bowel disease · Seattle

Inflammatory bowel disease clinical trials in Seattle

15 recruiting inflammatory bowel disease studies within range of Seattle. Click any trial for full eligibility criteria and contact info.

A Study to Assess the Safety and Efficacy of LB-P8 in Patients With PSC

NCT06699121 · Primary Sclerosing Cholangitis (PSC)
Recruiting

The study is designed to assess the safety and efficacy of LB-P8 in patients with primary sclerosing cholangitis.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereSacramento, California, United States + 6 more
SponsorLISCure Biosciences
▾Tap for details
Apply

Study of the Kono-S Anastomosis Versus the Side-to-side Functional End Anastomosis

NCT03256240 · Crohn's Disease
Recruiting

This study proposes a randomized prospective study comparing the Kono-S anastomosis to the standard side-to-side anastomosis.This will be a multi-center randomized prospective trial. Patients with Crohn's ileitis or Crohn's ileocolitis requiring resection will be randomized to undergo either the Kono-S anastomosis or the side-to-side functional end anastomosis.

PhaseNA
TypeInterventional
Age18 Years – 90 Years
WhereBoston, Massachusetts, United States + 14 more
SponsorWeill Medical College of Cornell University
▾Tap for details
Apply

Seattle Spatial Transcriptomic Research in Inflammatory Bowel Disease Evaluation (STRIDE)

Recruiting

This is a prospective observational study collecting long-term clinical data and samples for research in pediatric inflammatory bowel disease (IBD) patients with gut inflammation and a control cohort of pediatric patients with disorders of the brain-gut interactions (DBGI) with no detectable gut inflammation.

Phase—
TypeObservational
Age6 Years – 21 Years
WhereSeattle, Washington, United States
SponsorSeattle Children's Hospital
▾Tap for details
Apply

LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis

Recruiting

The main purpose of this study is to evaluate the safety and effectiveness of LY4268989 when compared to placebo in adult participants with moderately to severely active ulcerative colitis (UC). The study drug will be administered orally. The study will last up to approximately 108 weeks, excluding screening.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WherePhoenix, Arizona, United States + 257 more
SponsorEli Lilly and Company
▾Tap for details
Apply

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

NCT06233461 · Crohn's Disease
Recruiting

Crohn's disease (CD) is a long-lasting condition causing inflammation that can affect any part of the gut. The purpose of this study is to evaluate the efficacy and safety of TAK-279 versus placebo in participants with moderately to severely active Crohn's disease (CD). The main aim of this study is to learn if the 3 different doses of TAK-279 reduce bowel inflammation and ulcers in the bowel compared to the placebo after 12 weeks of treatment. Another aim is to compare any medical problems that participants have when they take TAK-279 or placebo and how well the participants tolerate medical problems. An endoscopy will be used to check the bowel for inflammation. The participants will be treated with TAK-279 for 52 weeks (1 year). During the study, participants will visit their study clinic 15 times.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereMurrieta, California, United States + 200 more
SponsorTakeda
▾Tap for details
Apply

A Study Investigating Oral Ozanimod (RPC1063) in Pediatric Participants With Moderate to Severe Active Ulcerative Colitis

NCT05076175 · Colitis, Ulcerative
Recruiting

The purpose of this study is to evaluate the effectiveness and safety of ozanimod (RPC1063) in achieving and maintaining clinical remission. Ozanimod will be administered orally to pediatric participants with moderate to severe active ulcerative colitis (UC) who have had an inadequate response to conventional therapy.

PhasePhase 2 / Phase 3
TypeInterventional
Age2 Years – 17 Years
WherePhoenix, Arizona, United States + 90 more
SponsorBristol-Myers Squibb
▾Tap for details
Apply

Study of Targeted Therapies for the Treatment of Adult Participants With Moderate to Severe Crohn's Disease

NCT06548542 · Crohn's Disease
Recruiting

Crohn's disease (CD) is a long-lasting disease that causes severe inflammation (redness, swelling), in the digestive tract, most frequently affecting the bowels. It can cause many different symptoms including belly pain, diarrhea, tiredness, and weight loss. Treatments are available but do not work the same for all patients or may stop working over time. This study will evaluate the effectiveness and adverse events of targeted therapies (TaTs) for adult participants with moderate to severe CD. The medicines assessed in this study are risankizumab, trosunilimab, lutikizumab, and ABBV-8736. When participants join the study, they will be randomized into available study treatment groups. Adult participants with CD will be enrolled. Around 590 participants will be enrolled in the study at approximately 300 sites worldwide. Risankizumab and trosunilimab are given as an injection under the skin or as an infusion into the vein. Lutikizumab is given as an injection under the skin. ABBV-8736 is given as an infusion into the vein. There may be higher treatment burden for participants in this trial compared to their standard of care treatment without participating in this study. Participants will attend regular visits during the study at a hospital or clinic. The effect of the treatment will be checked by medical assessments, blood tests, endoscopies, checking for side effects and completing questionnaires and a daily diary.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereDothan, Alabama, United States + 254 more
SponsorAbbVie
▾Tap for details
Apply

A Study to Test Whether BI 3032950 Helps People With Ulcerative Colitis

NCT06636656 · Ulcerative Colitis
Recruiting

Adults between 18 and 80 years of age with ulcerative colitis can participate in this study. This is a study for people for whom previous treatment was not successful or who stopped previous treatment. The purpose of this study is to find out whether BI 3032950 helps people with ulcerative colitis. This study has 2 parts. In Part A, participants get BI 3032950 as an infusion into a vein every 4 weeks. After 12 weeks, doctors check whether the signs and symptoms of ulcerative colitis have improved. Before the results of this assessment are available, participants move on to Part B and get BI 3032950 as an injection under the skin. Participants whose results show clinical response after 12 weeks can continue treatment with BI 3032950. They get BI 3032950 injections under the skin every 4 weeks for up to 2 years. Participants visit their doctors every 4 weeks. During these visits, the doctors check the signs and symptoms of ulcerative colitis. This includes taking blood and stool samples. Doctors also do endoscopies. This is a procedure that uses a tube with a camera to look inside the body. The doctors also regularly check participants' health and take note of any unwanted effects.

PhasePhase 2
TypeInterventional
Age18 Years – 80 Years
WhereScottsdale, Arizona, United States + 41 more
SponsorBoehringer Ingelheim
▾Tap for details
Apply
Recruiting

Brief Summary The aim of the FIBER study is to identify potential triggers associated with the later development of IBD (inflammatory bowel disease) based on baseline characteristics and biosamples (blood, urine, stool, saliva, and tissue). Aim 1: To identify clinical, demographic, and immunologic factors associated with an increased risk of developing IBD in family members of IBD patients. This aim will investigate the role of clinical factors (e.g., age of onset, gender, and family history), demographic factors (e.g., socioeconomic status, geographical location), and immune system markers (e.g., inflammatory cytokine profiles, immune cell populations) in predicting the likelihood of family members developing IBD over time. Aim 2: To examine dietary, environmental, and immunologic influences on the development of IBD in family members of IBD patients. This aim will explore how dietary habits (e.g., fiber, fats, processed foods), environmental exposures (e.g., smoking, pollution, and antibiotic use), and immune responses (e.g., changes in T-cell activation, inflammatory markers) contribute to the risk of IBD in family members. Aim 3: To analyze the multi-omic (metagenomic, transcriptomic, proteomic) cellular signatures of host and microbial signatures in family members of IBD patients and their association with IBD onset. This aim will investigate changes in the gut microbiome and immune-related gene expression profiles (transcriptomics) in family members. Specifically, the aim will focus on how shifts in microbial composition and host immune response genes (e.g., those involved in inflammation and epithelial barrier function) correlate with an increased risk of IBD development. Aim 4: To investigate the multi-omic (metabolomic, transcriptomic, proteomic) cellular signature of host and microbial signatures in family members to identify biomarkers predictive of IBD development. This aim will involve examining the metabolic, protein, and transcriptomic signatures (e.g., circulating cytokines, immune receptor expression) in blood, urine, or stool samples. The study will seek to identify early biomarkers from these profiles that can predict the onset of IBD, even in asymptomatic family members.

Phase—
TypeObservational
Age0 Years – 55 Years
WhereSeattle, Washington, United States
SponsorSeattle Children's Hospital
▾Tap for details
Apply

A Study of Long-acting Antibodies Alone and in Combinations for Moderate to Severe Ulcerative Colitis

Recruiting

This is a Phase 2, multicenter, proof-of-concept platform study in adult participants with moderately to severely active ulcerative colitis (UC). The primary goal of the study is to assess the efficacy and safety of multiple interventions following intravenous (IV) induction and subcutaneous (SC) maintenance treatment.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereCanoga Park, California, United States + 278 more
SponsorSpyre Therapeutics, Inc.
▾Tap for details
Apply

A Study to Evaluate the Efficacy and Safety of Tulisokibart (MK-7240) in Participants With Moderate to Severe Crohn's Disease (MK-7240-008)

NCT06430801 · Crohn's Disease
Recruiting

The purpose of this protocol is to evaluate the efficacy and safety of tulisokibart in participants with moderately to severely active Crohn's disease. Study 1's primary hypotheses are that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 52 (US/FDA and EU/EMA), and that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or per stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA). Study 2's primary hypothesis is that at least 1 tulisokibart dose level is superior to placebo in the proportion of participants achieving clinical remission per Crohn's Disease Activity Index score (\<150, US/FDA) or stool frequency and abdominal pain score (EU/EMA) and in the proportion of participants achieving endoscopic response at Week 12 (US/FDA and EU/EMA).

PhasePhase 3
TypeInterventional
Age16 Years – 80 Years
WhereDothan, Alabama, United States + 498 more
SponsorMerck Sharp & Dohme LLC
▾Tap for details
Apply

Efficacy and Safety of Obefazimod in Subjects With Moderately to Severely Active Crohn's Disease

Recruiting

This study has 3 treatment phases, a 12-Week Induction Phase, a 40-Week Maintenance Phase, and a 48-Week Extension Phase. The objective is to evaluate the efficacy and safety of obefazimod compared to placebo as induction and maintenance therapy in subjects with moderately to severely active CD after inadequate response (no response, loss of response, or intolerance) to conventional therapies and/or advanced therapies. The primary objective for the 48-Week Extension Phase is to evaluate the safety and tolerability of obefazimod compared with placebo in subjects who are enrolled in the Extension Phase.

PhasePhase 2
TypeInterventional
Age18 Years – 75 Years
WhereFairhope, Alabama, United States + 148 more
SponsorAbivax S.A.
▾Tap for details
Apply

A Study of Vedolizumab With and Without Upadacitinib in Adults With Crohn's Disease

NCT06227910 · Crohn's Disease
Recruiting

The main aim of this study is to learn whether vedolizumab and upadacitinib given together (also called dual targeted therapy or DTT) reduces bowel inflammation and ulcers in the bowel compared to vedolizumab only (also called monotherapy) in adults with moderately or severely active Crohn's Disease (CD) after 12 weeks of treatment. Other aims are to learn how safe and effective DTT is compared to monotherapy for these participants. All participants will receive DTT (either vedolizumab and upadacitinib or vedolizumab and placebo) for 12 weeks. Participants responding to the treatment will then receive vedolizumab only (monotherapy) for an additional 40 weeks. During the study, participants will visit their study clinic 15 times.

PhasePhase 3
TypeInterventional
Age18 Years – 65 Years
WhereLa Jolla, California, United States + 137 more
SponsorTakeda
▾Tap for details
Apply

A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease

NCT05509777 · Crohn's Disease
Recruiting

Study participants will be screened during the platform study and randomly assigned to receive mirikizumab or another intervention. The purpose of the mirikizumab study is to evaluate efficacy, safety, tolerability, and how well mirikizumab absorbs into the body of pediatric participants with Crohn's disease. Study periods for the intervention-specific appendix (ISA) will be as follows: * A 12-week induction period * A maintenance period from Week 12 to Week 52, and * A safety follow-up period up to 16 weeks. The study will last about 74 weeks and may include up to 19 visits.

PhasePhase 3
TypeInterventional
Age2 Years – 17 Years
WhereLos Angeles, California, United States + 80 more
SponsorEli Lilly and Company
▾Tap for details
Apply

Reverse-Engineering of Exclusive Enteral Nutrition (RE-EEN) in Crohn's Disease: A Multi-Center Trial

NCT06216899 · Crohn Disease
Recruiting

This study will compare the tolerability and efficacy of conventional formula Exclusive Enteral Nutrition (EEN) and whole-food blended smoothie EEN by enrolling a total of 60 participants with newly diagnosed pediatric Crohn's disease (CD). Participants will be provided either commercial formula or guided on the preparation of the home-blended smoothie. These participants will be given a specific recipe, blender, and be provided the food components to the smoothie. The study will total 8 weeks and will assess tolerance, clinical outcomes, stool microbiome, and quality of life.

PhaseNA
TypeInterventional
Age8 Years – 21 Years
WherePhiladelphia, Pennsylvania, United States + 2 more
SponsorSeattle Children's Hospital
▾Tap for details
Apply